Related Experiment Videos
Desmopressin in nocturnal enuresis.
1Department of Health, Central School Clinic, Turku, Finland.
The Journal of Urology
|April 1, 1991
Summary
Intranasal desmopressin significantly increased dry nights for children with primary nocturnal enuresis. This treatment was well-tolerated and effective across various doses, offering a promising solution for bedwetting.
Area of Science:
- Pediatrics
- Pharmacology
- Urology
Background:
- Primary nocturnal enuresis affects school-aged children, often resistant to conventional treatments.
- Previous therapies like water deprivation and imipramine showed limited success in many cases.
Purpose of the Study:
- To investigate the efficacy and safety of intranasal desmopressin for primary nocturnal enuresis.
- To evaluate different dosages of desmopressin in a dose-finding study.
Main Methods:
- A randomized, double-blind, placebo-controlled crossover study involving 52 children (5-13 years old).
- Patients received 20 micrograms desmopressin spray or placebo for 3-week periods, preceded and followed by control periods.
- An open-label, 3-month dose-finding and safety study evaluated 20, 30, and 40 microgram doses.
Main Results:
- Desmopressin significantly increased dry nights per week from 0.6 to 4.3-4.6 (p<0.01), compared to placebo responses of 2.1-2.4.
- In the dose-finding phase, 53% of patients achieved a full response, 19% intermediate, and 28% no response.
- Desmopressin was well-tolerated, with no adverse effects on weight or blood pressure.
Conclusions:
- Intranasal desmopressin is an effective treatment for primary nocturnal enuresis in children.
- The drug demonstrates good tolerance and efficacy across a range of doses (20-40 micrograms).
- Desmopressin offers a valuable therapeutic option for managing bedwetting in pediatric populations.